A pre-clinical study to evaluate the therapeutic potential of a bioelectronic platform in preventing and reducing inflammation in non-alcoholic steatohepatitis (NASH) is beginning, its developer, Endonovo Therapeutics, announced.
Fatty liver disease
FATTY LIVER DISEASE
NewsExposure to High-Fat Diet in Womb and During Breastfeeding Linked to Liver Disease
A child exposed to a mother’s high-fat diet while in the womb and breastfeeding is at greater risk of developing non-alcoholic fatty liver disease (NAFLD)…
Recent Posts
- Large VA study reveals hidden liver damage in US military veterans
- Uncle’s living donation saves 1-year-old girl with liver failure
- With FDA support, developer planning late-stage trial of belapectin for MASH
- A Q&A with med students helps to keep the ‘patient’ in patient care
- Heart risks in Alagille syndrome may go beyond artery narrowing